Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?

Copy For Citation

Eskazan A. E., Ozmen D.

EXPERT REVIEW OF HEMATOLOGY, vol.10, no.7, pp.583-586, 2017 (SCI-Expanded)

• Publication Type: Article / Editorial Material
• Volume: 10 Issue: 7
• Publication Date: 2017
• Doi Number: 10.1080/17474086.2017.1339599
• Journal Name: EXPERT REVIEW OF HEMATOLOGY
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Page Numbers: pp.583-586
• Istanbul University Affiliated: Yes